Injection Site Reaction to Extended-Release Buprenorphine (Sublocade
®
) for Opioid Use Disorder Fourteen Days after Administration
Kans J Med
.
2022 Aug 22:15:302-304.
doi: 10.17161/kjm.vol15.17931.
eCollection 2022.
Authors
Elizabeth Weesner
1
,
Hosain Ghassemi
1
,
Iryna Salapenka
2
,
Jaya Sri Konakanchi
1
,
Gregory Maggio
2
,
Roopa Sethi
2
Affiliations
1
University of Kansas School of Medicine, Kansas City, KS.
2
Department of Psychiatry and Behavioral Sciences, University of Kansas Health System, Kansas City, KS.
PMID:
36042837
PMCID:
PMC9409986
DOI:
10.17161/kjm.vol15.17931
No abstract available
Keywords:
buprenorphine; cellulitis; drug side effects; opioid use disorder; sublocade.
Publication types
Case Reports